Cargando…
Overall survival of individuals with metastatic cancer in Sweden: a nationwide study
AIMS: Consistent improvements for overall survival (OS) have been reported for individuals with metastatic cancer. Swedish population-based registers allow national coverage and long follow-up time. The aim of this study was to estimate and explore long-term OS of individuals diagnosed with metastat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563107/ https://www.ncbi.nlm.nih.gov/pubmed/36229841 http://dx.doi.org/10.1186/s12889-022-14255-w |
_version_ | 1784808324760338432 |
---|---|
author | Bütepage, Greta Carlqvist, Peter Jacob, Johanna Toft Hornemann, Asbjørn Vertuani, Simona |
author_facet | Bütepage, Greta Carlqvist, Peter Jacob, Johanna Toft Hornemann, Asbjørn Vertuani, Simona |
author_sort | Bütepage, Greta |
collection | PubMed |
description | AIMS: Consistent improvements for overall survival (OS) have been reported for individuals with metastatic cancer. Swedish population-based registers allow national coverage and long follow-up time. The aim of this study was to estimate and explore long-term OS of individuals diagnosed with metastatic cancer using Swedish nationwide health registers. METHODS: Individuals with metastatic breast (MBC), non-small cell lung (MNSCLC), ovary (MOC) or colorectal cancer (MCRC) or metastatic malignant melanoma (MMM) were identified in the Swedish national cancer register and national patient registers. Survival was estimated and stratified by available variables. Potential cure fractions were estimated using mixture cure models. RESULTS: In total, approximately 69,000 individuals were identified. The most common cancers were MCRC (36.2%) and MNSCLC (29.5%). Men were more frequently diagnosed with MNSCLC, MCRC, and MMM compared to women. Except for MOC, about 50% of individuals were 70 years or older at diagnosis. Throughout the study period survival differed across cancers. The longest median OS was observed for individuals with MOC and MBC. At 10 years of follow-up, the survival curves flatten at a survival rate of approximately 10% for all cancers except MNSCLC. The youngest age groups had the longest median OS. Increased survival was also observed for individuals diagnosed in 2015 and 2018 compared to individuals diagnosed during earlier years. The estimated cure fractions were 4% for MBC, 1.5% for MNSCLC, 6.8% for MCRC, 8.6% for MOC and MMM. CONCLUSIONS: Long-term survival has been assessed across all indications except for NSCLC.. The findings may be relevant for healthcare planning to meet the needs of future patients and potential long-term survivors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14255-w. |
format | Online Article Text |
id | pubmed-9563107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95631072022-10-15 Overall survival of individuals with metastatic cancer in Sweden: a nationwide study Bütepage, Greta Carlqvist, Peter Jacob, Johanna Toft Hornemann, Asbjørn Vertuani, Simona BMC Public Health Research AIMS: Consistent improvements for overall survival (OS) have been reported for individuals with metastatic cancer. Swedish population-based registers allow national coverage and long follow-up time. The aim of this study was to estimate and explore long-term OS of individuals diagnosed with metastatic cancer using Swedish nationwide health registers. METHODS: Individuals with metastatic breast (MBC), non-small cell lung (MNSCLC), ovary (MOC) or colorectal cancer (MCRC) or metastatic malignant melanoma (MMM) were identified in the Swedish national cancer register and national patient registers. Survival was estimated and stratified by available variables. Potential cure fractions were estimated using mixture cure models. RESULTS: In total, approximately 69,000 individuals were identified. The most common cancers were MCRC (36.2%) and MNSCLC (29.5%). Men were more frequently diagnosed with MNSCLC, MCRC, and MMM compared to women. Except for MOC, about 50% of individuals were 70 years or older at diagnosis. Throughout the study period survival differed across cancers. The longest median OS was observed for individuals with MOC and MBC. At 10 years of follow-up, the survival curves flatten at a survival rate of approximately 10% for all cancers except MNSCLC. The youngest age groups had the longest median OS. Increased survival was also observed for individuals diagnosed in 2015 and 2018 compared to individuals diagnosed during earlier years. The estimated cure fractions were 4% for MBC, 1.5% for MNSCLC, 6.8% for MCRC, 8.6% for MOC and MMM. CONCLUSIONS: Long-term survival has been assessed across all indications except for NSCLC.. The findings may be relevant for healthcare planning to meet the needs of future patients and potential long-term survivors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14255-w. BioMed Central 2022-10-14 /pmc/articles/PMC9563107/ /pubmed/36229841 http://dx.doi.org/10.1186/s12889-022-14255-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bütepage, Greta Carlqvist, Peter Jacob, Johanna Toft Hornemann, Asbjørn Vertuani, Simona Overall survival of individuals with metastatic cancer in Sweden: a nationwide study |
title | Overall survival of individuals with metastatic cancer in Sweden: a nationwide study |
title_full | Overall survival of individuals with metastatic cancer in Sweden: a nationwide study |
title_fullStr | Overall survival of individuals with metastatic cancer in Sweden: a nationwide study |
title_full_unstemmed | Overall survival of individuals with metastatic cancer in Sweden: a nationwide study |
title_short | Overall survival of individuals with metastatic cancer in Sweden: a nationwide study |
title_sort | overall survival of individuals with metastatic cancer in sweden: a nationwide study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563107/ https://www.ncbi.nlm.nih.gov/pubmed/36229841 http://dx.doi.org/10.1186/s12889-022-14255-w |
work_keys_str_mv | AT butepagegreta overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy AT carlqvistpeter overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy AT jacobjohanna overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy AT tofthornemannasbjørn overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy AT vertuanisimona overallsurvivalofindividualswithmetastaticcancerinswedenanationwidestudy |